Vesugen
/ Khavinson-tradition tripeptide (Lys-Glu-Asp); proposed vascular endothelium bioregulatorALIAS · KED · Lys-Glu-Asp · Vascular peptide bioregulator
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. Vesugen is the trade designation in the Khavinson school for the synthetic tripeptide Lys-Glu-Asp (KED), proposed as a vascular-endothelium peptide bioregulator. The molecule is a defined chemical entity (unlike fractionated cytogen extracts), but its proposed pharmacology rests on the Khavinson laboratory's broader peptide-bioregulator hypothesis and has not been independently replicated under contemporary Western trial methodology.
The Khavinson programme proposes that short peptides such as KED bind directly to specific DNA sequences and modulate transcription in a tissue-selective manner, with KED specifically positioned as a vascular-endothelium regulator. Cell-culture and rodent studies from the Saint Petersburg group describe effects on endothelial gene expression, vascular wall remodelling markers, and age-related vascular function; the mechanistic framework (direct DNA binding by tripeptides) remains a single-school claim that the broader transcription-factor literature has not adopted.
Tier 4. The published evidence base is dominated by the Khavinson group's own primary work, much of which appears in Russian-language journals and review chapters. PubMed-indexed English-language KED tripeptide literature is sparse and largely descriptive. No Phase 1 or later trial in Western literature.
No formal Phase 1 human safety database in Western literature. Russian sources report good tolerability within the bioregulator clinical tradition.
Regulatory status
- FDA status:
- Not FDA-approved
Russian-origin literature without independent Western replication. The proposed direct-DNA-binding mechanism for short peptides is a foundational claim of the Khavinson programme that remains controversial outside it. Vendor-sold KED material is sold as a chemically defined tripeptide but the pharmacological claims accompanying it derive from the unreplicated bioregulator literature.